JPMorgan Chase & Co. Raises Insmed (NASDAQ:INSM) Price Target to $72.00
Insmed (NASDAQ:INSM – Free Report) had its target price lifted by JPMorgan Chase & Co. from $55.00 to $72.00 in a report issued on Thursday morning, Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock. INSM has been the topic of a number of other research reports. Wells Fargo & Company […]
More Stories
How Inventory Allocation Across Multiple Warehouses Can Reduce Delivery Times and Costs
A shopper in Seattle orders a pair of running shoes. Whether that package arrives quickly and cheaply depends on a...
Wall Street Review: Small Caps Outperform as Bond Yields Ease
By Panos Mourdoukoutas Small-cap stocks outperformed this week as investors rotated out of the volatile AI trade and into interest-rate-sensitive...
Judge Rejects Bail for Former OpenAI Employee Accused of Installing Listening Device
By Lear Zhou SAN FRANCISCO—A federal judge rejected a bail request of a former OpenAI engineer who was accused of...
Trump Announces $4.2 Billion Audi Auto Manufacturing Investment in Georgia
By Travis Gillmore PERRY, Ga.– President Donald Trump unveiled a $4.2 billion investment from automaker Audi to develop its first...
DOJ Gives California County Election Officials 48 Hours to Help Verify Voters’ Citizenship
By Tom Gantert The U.S. Department of Justice has sent letters to county election officials in California warning them they...
French Officials Say 1,300 Arrests Made Amid Latest Unrest
By Jack Phillips More than 1,300 people were arrested in another day of protests and riots, after a mass march...